41
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Targeted therapy in lung cancers: hopes and challenges

&
Pages 659-661 | Published online: 10 Jan 2014

References

  • Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc.83(5), 584–594 (2008).
  • Herbst RS, Heymach JV, Lippman SM. Lung cancer. N. Engl. J. Med.359(13), 1367–1380 (2008).
  • Vilmar AC, Sorensen JB. Customising chemotherapy in advanced non-small cell lung cancer: daily practice and perspectives. Eur. Respir. Rev.20(119), 45–52 (2011).
  • Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat. Rev. Drug Discov.9(10), 767–774 (2010).
  • Fruh M. The search for improved systemic therapy of non-small cell lung cancer – what are today’s options? Lung Cancer72(3), 265–270 (2011).
  • Looyenga BD, Cherni I, Mackeigan JP, Weiss GJ. Tailoring tyrosine kinase inhibitors to fit the lung cancer genome. Transl. Oncol.4(2), 59–70 (2011).
  • Ding L, Getz G, Wheeler DA et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature455(7216), 1069–1075 (2008).
  • Socinski MA. Multitargeted receptor tyrosine kinase inhibition: an antiangiogenic strategy in non-small cell lung cancer. Cancer Treat. Rev. DOI: 10.1016/j.ctrv.2011.04.003 (2011) (Epub ahead of print).
  • Lu C, Kamat AA, Lin YG et al. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin. Cancer Res.13(14), 4209–4217 (2007).
  • Ellis LM, Hicklin DJ. Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clin. Cancer Res.15(24), 7471–7478 (2009).
  • Horn L, Castellanos EL, Johnson DH. Update on new drugs in small cell lung cancer. Expert Opin. Investig. Drugs20(4), 441–445 (2011).
  • Custodio A, Mendez M, Provencio M. Targeted therapies for advanced non-small-cell lung cancer: current status and future implications. Cancer Treat. Rev. DOI: 10.1016/j.ctrv.2011.04.001 (2011) (Epub ahead of print).
  • Marko-Varga G, Fehniger TE, Rezeli M, Dome B, Laurell T, Vegvari A. Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging. J. Proteomics74(7), 982–992 (2011).
  • Tonra JR, Deevi DS, Corcoran E et al. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin. Cancer Res.12(7 Pt 1), 2197–2207 (2006).
  • Syrigos KN, Saif MW, Karapanagiotou EM, Oikonomopoulos G, De Marinis F. The need for third-line treatment in non-small cell lung cancer: an overview of new options. Anticancer Res.31(2), 649–659 (2011).
  • Baumgartner C, Osl M, Netzer M, Baumgartner D. Bioinformatic-driven search for metabolic biomarkers in disease. J. Clin. Bioinform.1(1), 2 (2011).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.